Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma.

This Phase III randomized controlled trial evaluates the effectiveness and toxicity profile of a modified DHAP regimen compared to the standard DHAP regimen in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The DHAP regimen (cisplatin, cytarabine, dexamethasone) is widely used as salvage therapy but is associated with significant toxicities, including renal dysfunction and severe myelosuppression. The modified DHAP protocol fractionates cisplatin and cytarabine administration to reduce nephrotoxicity, improve tolerability, and potentially allow outpatient treatm

Trial Details

NCT ID
NCT07739654
Phase
PHASE3
Sponsor
King Edward Medical University
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • Cisplatin (modified schedule)
  • Cisplatin
  • Dexametasone
  • Cytarabine (Ara-C)
  • Cytarabine (Ara-C) (Modified schedule)
Locations (sample)
  • Lahore, Punjab Province, Pakistan|31.558,74.35071

Key Eligibility Criteria

  • Histologically confirmed relapsed or refractory DLBCL
  • Adults ≥ 18 years
  • At least one prior line of therapy for lymphoma
  • ECOG performance status 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →